{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T11:54:56Z","timestamp":1773143696889,"version":"3.50.1"},"reference-count":45,"publisher":"Oxford University Press (OUP)","issue":"Supplement_1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2005,7,1]]},"DOI":"10.1086\/429497","type":"journal-article","created":{"date-parts":[[2005,6,2]],"date-time":"2005-06-02T14:42:33Z","timestamp":1117723353000},"page":"S56-S62","source":"Crossref","is-referenced-by-count":12,"title":["Delivering Therapy for Hepatitis C Virus Infection to Incarcerated HIV-Seropositive Patients"],"prefix":"10.1093","volume":"41","author":[{"given":"Barbara","family":"McGovern","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Fiore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alysse","family":"Wurcel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Taglienti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meg","family":"Bradley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Galvin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Libone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean","family":"Ramsey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valerie","family":"Molinaro-Gudas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Drewniak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carol","family":"Amick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anjali","family":"Andalkar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harriet","family":"Scheft","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ioana","family":"Bica","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2005,7,1]]},"reference":[{"key":"key\n\t\t\t\t20171014013402_ref1","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1086\/318501","article-title":"Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection","volume":"32","author":"Bica","year":"2001","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20171014013402_ref2","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1086\/321909","article-title":"Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis","volume":"33","author":"Graham","year":"2001","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20171014013402_ref3","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/hep.1840360703","article-title":"National Institutes of Health Consensus Development Conference Statement: management of hepatitis C: 2002\u2014June 12-12, 2002","volume":"36","author":"National Institutes of Health","year":"2002","journal-title":"Hepatology"},{"key":"key\n\t\t\t\t20171014013402_ref4","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1086\/344907","article-title":"Hepatitis C virus and human immunodeficiency virus coinfection in an urban population: low eligibility for interferon treatment","volume":"36","author":"Fleming","year":"2003","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20171014013402_ref5","first-page":"126","article-title":"Barriers to hepatitis C treatment among patients co-infected with HIV [abstract 597]","volume-title":"Program and abstracts of the 41st annual meeting of the Infectious Diseases Society of America (San Diego)","author":"Short","year":"2003"},{"key":"key\n\t\t\t\t20171014013402_ref6","first-page":"135","article-title":"The complexities of managing HIV\/HCV co-infection in a public health clinic serving community and incarcerated patients [abstract 520]","volume-title":"Program and abstracts of the 40th annual meeting of the Infectious Diseases Society of America (Chicago)","author":"McGovern","year":"2002"},{"key":"key\n\t\t\t\t20171014013402_ref7","first-page":"124","article-title":"Renal dysfunction in HIV\/HCV co-infected patients receiving interferon and ribavirin [abstract 593]","volume-title":"Program and abstracts of the 41st annual meeting of the Infectious Diseases Society of America (San Diego)","author":"Bica","year":"2003"},{"key":"key\n\t\t\t\t20171014013402_ref8","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1097\/00002030-200305020-00011","article-title":"Pegylated IFN-alpha2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients","volume":"17","author":"Perez-Olmeda","year":"2003","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20171014013402_ref9","article-title":"Validation of self-reported risk as a method for identifying anti-hepatitis C positive individuals at time of intake physical examination at Massachusetts Department of Correction facilities","volume-title":"Program and abstracts of the National Conference on Correctional Health Care (St. Louis)","author":"Eastman","year":"2001"},{"key":"key\n\t\t\t\t20171014013402_ref10","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1056\/NEJM199908193410802","article-title":"The prevalence of hepatitis C virus infection in the United States 1988 through 1994","volume":"341","author":"Alter","year":"1999","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20171014013402_ref11","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1053\/gast.2002.35950","article-title":"Adherence to combination therapy enhances sustained response in genotype-1 infected patients with chronic hepatitis C","volume":"123","author":"McHutchison","year":"2002","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20171014013402_ref12","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1111\/j.1572-0241.2004.30310.x","article-title":"Treatment of chronic hepatitis C virus in the Virginia department of corrections: can compliance overcome racial differences to response?","volume":"99","author":"Sterling","year":"2004","journal-title":"Am J Gastroenterol"},{"key":"key\n\t\t\t\t20171014013402_ref13","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1053\/jhep.2003.50031","article-title":"Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin psychiatric risk groups","volume":"37","author":"Schaefer","year":"2003","journal-title":"Hepatology"},{"key":"key\n\t\t\t\t20171014013402_ref14","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1086\/375065","article-title":"Extending treatment for HCV infection to HIV-HCV coinfected individuals with psychiatric illness and drug dependence","volume":"36","author":"Taylor","year":"2003","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20171014013402_ref15","article-title":"RIBAVIC trial (ANRS HC02): a controlled randomized trial of pegylated interferon alfa-2b plus ribavirin vs interferon alfa-2b plus ribavirin for the initial treatment of chronic hepatitis C in HIV co-infected patients: preliminary results [abstract LbOr16]","volume-title":"Program and abstracts of the XIV International AIDS Conference (Barcelona)","author":"Perronne","year":"2002"},{"key":"key\n\t\t\t\t20171014013402_ref16","first-page":"102","article-title":"A randomized, controlled trial of pegylated interferon-alfa 2a with ribavirin vs. interferon-alfa with ribavirin for the treatment of chronic HCV in HIV co-infection: ACTG A5071","volume-title":"Program and abstracts of the 9th Conference on Retroviruses and Opportunistic Infections (Seattle)","author":"Chung","year":"2002"},{"key":"key\n\t\t\t\t20171014013402_ref17","first-page":"117","article-title":"Final results of APRICOT: a randomized, partially blinded international trial evaluating peginterferon-alfa 2a + ribavirin vs. interferon alfa 2a + ribavirin in the treatment of HCV in HIV\/HCV co-infection [abstract 112]","volume-title":"Program and abstracts of the 11th Conference on Retroviruses and Opportunistic Infections (San Francisco)","author":"Torriani","year":"2004"},{"key":"key\n\t\t\t\t20171014013402_ref18","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1086\/315283","article-title":"Hepatitis C virus in lymphoid cells of patients coinfected with human immunodeficiency virus type 1: evidence of active replication in monocytes\/macrophages and lymphocytes","volume":"181","author":"Laskus","year":"2000","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20171014013402_ref19","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1056\/NEJM199811193392101","article-title":"Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group","volume":"339","author":"McHutchison","year":"1998","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20171014013402_ref20","doi-asserted-by":"crossref","first-page":"346","DOI":"10.7326\/0003-4819-140-5-200403020-00010","article-title":"Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose","volume":"140","author":"Hadziyannis","year":"2004","journal-title":"Ann Intern Med"},{"key":"key\n\t\t\t\t20171014013402_ref21","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1097\/00002030-200111090-00010","article-title":"Long-term efficacy of combination therapy with interferon-alfa2b and ribavirin for severe chronic hepatitis C in HIV-infected patients","volume":"15","author":"Landau","year":"2001","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20171014013402_ref22","first-page":"2491","article-title":"Once-weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alfa","volume":"98","author":"Dieterich","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"key\n\t\t\t\t20171014013402_ref23","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1182\/blood.V84.4.1020.1020","article-title":"Increasing hepatitis C virus RNA levels in hemophiliacs: relationship to human immunodeficiency virus infection and liver disease","volume":"84","author":"Eyster","year":"1994","journal-title":"Blood"},{"key":"key\n\t\t\t\t20171014013402_ref24","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1086\/379255","article-title":"Hepatitis C virus (HCV) and human immunodeficiency virus (HIV) dynamics during HCV treatment in HCV\/HIV coinfection","volume":"188","author":"Torriani","year":"2003","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20171014013402_ref25","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1086\/374837","article-title":"Interferon-ribavirin in association with stavudine has no impact on plasma human immunodeficiency virus type 1 level in patients coinfected with HIV and hepatitis C virus: a CORIST-ANRS HC1 trial","volume":"36","author":"Salmon-Ceron","year":"2003","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20171014013402_ref26","first-page":"364","article-title":"Final results of daily vs. 3-times weekly interferon alfa-2b plus ribavirin (RBV) for the treatment of hepatitis C virus (HCV) in HIV-infected persons: a multi-center, randomized open-label study","volume-title":"Program and abstracts of the 10th Conference on Retroviruses and Opportunistic Infections (Boston)","author":"Sulkowski","year":"2003"},{"key":"key\n\t\t\t\t20171014013402_ref27","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1053\/jhep.2002.32094","article-title":"Risk of HAART therapy in hepatitis C","volume":"35","author":"McGovern","year":"2002","journal-title":"Hepatology"},{"key":"key\n\t\t\t\t20171014013402_ref28","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1097\/00002030-200103300-00011","article-title":"Incidence of pancreatitis in HIV-infected patients receiving nucleoside reverse transcriptase inhibitor drugs","volume":"15","author":"Moore","year":"2001","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20171014013402_ref29","doi-asserted-by":"crossref","first-page":"21509","DOI":"10.1016\/S0021-9258(18)54668-8","article-title":"Mechanism of the potentiating effect of ribavirin on the activity of 2\u2032,3\u2032-dideoxyinosine against human immunodeficiency virus","volume":"266","author":"Balzarini","year":"1991","journal-title":"J Biol Chem"},{"key":"key\n\t\t\t\t20171014013402_ref30","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1093\/infdis\/173.4.840","article-title":"Combination therapy with didanosine and interferon-alpha in human immunodeficiency virus-infected patients: results of a phase I\/II trial","volume":"173","author":"Kovacs","year":"1996","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20171014013402_ref31","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1097\/00002030-200312050-00019","article-title":"Didanosine-ribavirin combination: synergistic combination in vitro, but high potential risk of toxicity in vivo","volume":"17","author":"Bruno","year":"2003","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20171014013402_ref32","first-page":"283","article-title":"Concomitant DDI\/D4T and interferon\/ribavirin treatments may induce a high risk of mitochondrial toxicity in HIV\/HCV co-infected patients (ANRS HC02-RIBAVIC study) [abstract 481]","volume-title":"Program and abstracts of the Annual Meeting of the American Association for the Study of Liver Disease (Boston)","author":"Hor","year":"2002"},{"key":"key\n\t\t\t\t20171014013402_ref33","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1002\/hep.20107","article-title":"Treatment of chronic hepatitis C in HIV\/HCV coinfection with interferon alfa-2b + full-course vs. 16-week delayed ribavirin","volume":"39","author":"Brau","year":"2004","journal-title":"Hepatology"},{"key":"key\n\t\t\t\t20171014013402_ref34","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1002\/hep.510300409","article-title":"Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients","volume":"30","author":"Benhamou","year":"1999","journal-title":"Hepatology"},{"key":"key\n\t\t\t\t20171014013402_ref35","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1053\/jhep.2001.29201","article-title":"The influence of human immunodeficiency virus coinfection on chronic hepatitis C in injection drug users: a long-term retrospective cohort study","volume":"34","author":"DiMartino","year":"2001","journal-title":"Hepatology"},{"key":"key\n\t\t\t\t20171014013402_ref36","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1086\/367643","article-title":"Progression of chronic hepatitis C to liver fibrosis and cirrhosis in patients coinfected with hepatitis C virus and human immunodeficiency virus","volume":"36","author":"Martinez-Sierra","year":"2003","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20171014013402_ref37","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1086\/317644","article-title":"Liver fibrosis progression is related to CD4 cell depletion in patients coinfected with hepatitis C virus and human immunodeficiency virus","volume":"183","author":"Puoti","year":"2001","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20171014013402_ref38","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1136\/gut.52.7.1035","article-title":"Impact of human immunodeficiency virus infection on the progression of liver fibrosis in hepatitis C virus infected patients","volume":"52","author":"Mohsen","year":"2003","journal-title":"Gut"},{"key":"key\n\t\t\t\t20171014013402_ref39","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1086\/380130","article-title":"Incidence of predictors of severe liver fibrosis in human immunodeficiency virus-infected patients with chronic hepatitis C: a European collaborative study","volume":"38","author":"Martin-Carbonero","year":"2004","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20171014013402_ref40","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/j.1572-0241.2001.03374.x","article-title":"Hepatocellular carcinoma in HIV-infected patients with chronic hepatitis C","volume":"96","author":"Garcia-Samaniego","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"key\n\t\t\t\t20171014013402_ref41","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1128\/AAC.44.4.821-826.2000","article-title":"Single-dose pharmacokinetics of amprenavir, a human immunodeficiency virus type 1 protease inhibitor, in subjects with normal or impaired hepatic function","volume":"44","author":"Veronese","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171014013402_ref42","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1002\/hep.510230607","article-title":"The long-term pathological evolution of chronic hepatitis C","volume":"23","author":"Yano","year":"1996","journal-title":"Hepatology"},{"key":"key\n\t\t\t\t20171014013402_ref43","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1097\/00002030-200204120-00001","article-title":"Care of patients with chronic hepatitis C and HIV co-infection: recommendations from the HIV-HCV international panel","volume":"16","author":"Soriano","year":"2002","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20171014013402_ref44","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.2105\/AJPH.92.11.1789","article-title":"The burden of infectious disease among inmates and releasees from US correctional facilities, 1997","volume":"92","author":"Hammett","year":"2002","journal-title":"Am J Public Health"},{"key":"key\n\t\t\t\t20171014013402_ref45","doi-asserted-by":"crossref","first-page":"187","DOI":"10.7326\/0003-4819-138-3-200302040-00010","article-title":"Treatment of chronic hepatitis C in a state correctional facility","volume":"138","author":"Allen","year":"2003","journal-title":"Ann Intern Med"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/41\/Supplement_1\/S56\/20906926\/41-Supplement_1-S56.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,11]],"date-time":"2021-07-11T12:26:14Z","timestamp":1626006374000},"score":1,"resource":{"primary":{"URL":"http:\/\/academic.oup.com\/cid\/article\/41\/Supplement_1\/S56\/400428\/Delivering-Therapy-for-Hepatitis-C-Virus-Infection"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,7,1]]},"references-count":45,"journal-issue":{"issue":"Supplement_1","published-online":{"date-parts":[[2005,7,1]]},"published-print":{"date-parts":[[2005,7,1]]}},"URL":"https:\/\/doi.org\/10.1086\/429497","relation":{},"ISSN":["1537-6591","1058-4838"],"issn-type":[{"value":"1537-6591","type":"electronic"},{"value":"1058-4838","type":"print"}],"subject":[],"published-other":{"date-parts":[[2005,7,1]]},"published":{"date-parts":[[2005,7,1]]}}}